Merck Announces Phase 3 KEYNOTE-942 Results for Keytruda Plus mRNA Cancer Vaccine in Melanoma

Merck today announced results from the Phase 3 KEYNOTE-942 trial evaluating KEYTRUDA (pembrolizumab) plus mRNA-4157/V940, a personalized mRNA cancer vaccine developed with Moderna, in patients with resected high-risk melanoma. The trial met its primary endpoint, demonstrating a statistically significant improvement in recurrence-free survival compared to KEYTRUDA alone. The 2-year RFS rate was 74.8% for KEYTRUDA plus mRNA-4157 versus 55.6% for KEYTRUDA alone. These results represent a landmark achievement in personalized cancer immunotherapy and support regulatory submissions for this combination.